VistaGen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on August 2, 2013, covering events occurring on July 30, 2013. The filing details the creation of a direct financial obligation and the unregistered sale of equity securities to Platinum Long Term Growth VII, LLC ("Platinum").
Key Financial Metrics and Obligations
- Debt Issuance: The Company issued a senior secured convertible promissory note with a principal amount of $250,000.
- Interest Rate: The note accrues interest at 10% per annum.
- Maturity Date: July 26, 2016, if not exchanged or converted earlier.
- Repayment Terms: Principal and accrued interest are payable via the issuance of restricted shares of common stock if not exchanged for other securities.
- Equity Component: The Company issued a five-year warrant to purchase 250,000 shares of common stock at an exercise price of $0.50 per share.
- Collateral: The note is secured by a continuing security interest in all assets of the Company and certain assets of its wholly owned subsidiaries.
Material Changes and Conversion Triggers
The filing introduces a new debt obligation and potential equity dilution. A material feature of the note is an automatic conversion trigger: the note shall automatically convert into "Exchange Securities" if the Company receives gross proceeds of at least $10.0 million from the sale of common stock to Autilion AG or its affiliates/nominees. Additionally, Platinum holds the right to exchange amounts due under the note for securities offered by the Company to finance short-term working capital needs.
Outlook, Risks, and Use of Proceeds
The proceeds from the sale of the note and the potential exercise of the warrant are expected to be used for general corporate purposes. The securities were sold in transactions exempt from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D, with Platinum representing itself as an accredited investor. The filing includes a disclaimer that the descriptions of the note and warrant are qualified by reference to the full text of the attached exhibits.
Investor Verification Checklist
- Verify the full terms of the Senior Secured Convertible Promissory Note (Exhibit 10.1) regarding repayment conditions and conversion mechanics.
- Review the Warrant agreement (Exhibit 10.2) for specific exercise conditions and expiration details.
- Monitor the status of the potential $10.0 million financing from Autilion AG, which would trigger automatic conversion of the note.
- Assess the impact of the 10% interest rate and potential share issuance on existing shareholder dilution.
- Confirm the current status of the security interests in Company assets previously disclosed in the October 16, 2012, Form 8-K.